gms | German Medical Science

60. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit den Benelux-Ländern und Bulgarien

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

24. - 27.05.2009, Münster

Impact of the combination of ALA-guided surgery and concomitant radiochemotherapy on survival of glioblastoma patients

Meeting Abstract

  • P. Slotty - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf
  • W. Stummer - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf
  • M. Göppert - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf
  • H.-J. Steiger - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf
  • M. Sabel - Neurochirurgische Klinik, Heinrich-Heine-Universität Düsseldorf

Deutsche Gesellschaft für Neurochirurgie. 60. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit den Benelux-Ländern und Bulgarien. Münster, 24.-27.05.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. DocMI.09-06

doi: 10.3205/09dgnc235, urn:nbn:de:0183-09dgnc2350

Veröffentlicht: 20. Mai 2009

© 2009 Slotty et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Objective: Throughout the past years, the primary therapy of glioblastoma has changed due to the introduction of ALA-fluorescence guided resection and concomitant radiochemotherapy according to the Stupp-scheme. The impact of these modifications on the prognosis of glioblastoma patients were the subject of this analysis.

Methods: Since 1998 epidemiological and clinical data on glioma patients were collected in the neurooncological database of our department. For the present analysis, 175 surgically treated, primary glioblastoma patients from the years 2000 to 2005 were classified according to surgery with or without ALA and adjuvant therapy with or without concomitant therapy.

Results: Patients not subjected to fluorescence-guided resections, nor to concomitant radiochemotherapy had a median survival time of only 11.4 months. In comparison, patients treated with fluorescence-guided resections and adjuvant concomitant radiochemotherapy survived a median of 16.7 months. ALA-guided resection significantly correlated with complete resections (p=0.012) and improved overall survival (9.5 months vs 16.9 months) (p=0.006). These groups did not significantly differ regarding age and pre-surgery Karnofsky Performance Score (KPS).

Conclusions: This single institution analysis mirrors that advances made in neurooncology during the last years, such as improved resections and radiochemotherapy using temozolomide, have had a significant impact on the outcome of patients with malignant gliomas.